Piramal Pharma Releases FY26 Business Responsibility & Sustainability Report

Piramal Pharma Limited (PPL) has submitted its Business Responsibility & Sustainability Report (BRSR) for the Financial Year 2025-26, along with an Independent Auditor’s Limited Assurance Report. This report forms a part of the Annual Report for the said financial year, as required by Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The report provides comprehensive disclosures on PPL's operations, including its corporate identity, registered office, financial year of reporting (April 1, 2025, to March 31, 2026), and stock exchange listings on NSE and BSE. The company's paid-up capital is ₹1,329.25 Crores. The BRSR details PPL's business activities, which primarily involve the manufacturing of pharmaceuticals, medicinal, chemical, and botanical products, contributing 100% to its turnover. The company serves over 100 countries, with exports accounting for 72.78% of its total turnover.

Significant data on employees and workers is presented, detailing permanent and other than permanent staff, with a total of 6,774 employees and 3,666 workers as of the financial year-end. The report also highlights the participation of women in leadership roles, with 30% on the Board of Directors and 50% in Key Management Personnel roles. Furthermore, PPL has provided details of its holding, subsidiary, and associate companies, including 22 subsidiaries and 2 associate companies. The report also covers CSR details, stating that CSR is applicable, with a turnover of ₹4,782.01 Crores and a net worth of ₹8,859.47 Crores on a standalone basis.

The BRSR includes extensive information on material responsible business conduct issues, covering areas such as business ethics, patient centricity, data privacy, product quality, financial performance, regulatory compliance, accessibility, asset integrity, business continuity, climate action, corporate governance, employee health and safety, energy management, human capital development, operational excellence, product sustainability, R&D, responsible investment, risk management, stakeholder relationships, supply chain management, technology adoption, water and waste management, air emissions, community development, ecosystem and biodiversity, human rights, and product tracking. The company has set specific goals for reducing Scope 1 and Scope 2 emissions by 42% by FY 2030 and Scope 3 emissions by 25% by FY 2030, aligned with Science-Based Targets initiative (SBTi) pathways. The report also details management processes, policies, and governance structures, including the role of the Sustainability and Risk Management Committee.